CIP2A overexpression in Taiwanese oral cancer patients

Figures & data

Table 1 Demographic and characteristics among oral cancer patients

Factors	n	%
Gender
Female	8	6
Male	125	94
Age, years
≤49	36	29.3
50–59	47	35.3
60–69	33	24.8
≥70	14	10.6
T (tumor size)
I	38	28.6
II	45	33.8
III	10	7.5
IV	40	30.1
N (lymph node)
N0	98	73.7
N1	14	10.5
N2	21	15.8
N3	0	0
M (metastasis)
No	133	100
Yes	0	0
AJCC cancer stage
I	34	19.8
II	34	20.9
III	14	11.6
IV	51	47.8
Histological grade
Well	21	15.7
Moderate	111	81.3
Poor	1	3
Clinical therapy
Surgery	58	43.6
Radiotherapy	64	48.1
Chemotherapy	11	8.2
Chemoradiotherapy	15	11.2

Abbreviation: AJCC, American Joint Committee on Cancer.

Figure 1 Higher expression levels of CIP2A in OSCCs. (A) Representative immunohistochemical expression patterns of CIP2A in nontumor tissues and OSCC specimens are shown. (B) Kaplan–Meier survival curves showing the difference of survival time between patients with low- and high-expression CIP2A on OSCC samples from 133 patients.Abbreviations: CIP2A, cancerous inhibitor of protein phosphatase 2A; OSCC, oral squamous cell carcinoma.

Table 2 Clinicopathologic factors associated with CIP2A expression

	Cytoplasm
	CIP2A
Factors	Low	High
	Number	Number
(n = 58)	(n=75)	aOR^a (95% CI)	P-value
Tumor size (SD)	3.16 (1.60)	2.81 (1.68)
T classification
I/II	31	52	1
III/IV	27	23	0.49 (0.24–1.03)	0.058
N (lymph node)
N0/N1	48	64	1
N2/N3	10	11	0.77 (0.30–1.99)	0.591
M (metastasis)
No	57	75	1
Yes	1	0	ND
AJCC cancer stage
I/II	25	43	1
III/IV	33	32	0.53 (0.26–1.07)	0.074
Histological grade
Well	4	17	1
Moderate/poor	54	58	0.25 (0.08–0.81)	0.020
Death
No	23	36	1
Yes	35	39	0.55 (0.27–1.15)	0.113

Notes: ^aAdjusted odds ratio (aOR) was controlled for gender and age.

Abbreviations: ND, not determined; CIP2A, cancerous inhibitor of protein phosphatase 2A; AJCC, American Joint Committee on Cancer.

Table 3 The effect of clinicopathologic factor and CIP2A expression on mortality density and adjusted hazard ratio (aHR) among OSCC patients

Factors	Number of patients	Follow-up	Number of death	Mortality density^a	aHR^b	(95% CI)	Interaction
(person-year)	P-value
Overall mortality from primary malignancy to death
T classification
I/II	83	554.9	22	4.0	1
III/IV	50	242	26	10.7	1.9	(1.4–2.8)	0.0707
N classification
N0/N1	112	736.4	33	4.5	1
N2/N3	21	60.5	15	24.8	2.9	(2.0–4.1)	<0.0001
AJCC tumor stage
I/II	68	483.1	16	3.3	1
III/IV	65	313.7	32	10.2	2.5	(1.7–3.7)	0.0051
Histological grade
Well	21	160.1	0	0.0	1
Moderate/poor	112	636.7	48	7.5	2.9	(1.4–5.6)	0.0682
CIP2A expression
High	75	455.7	23	5.0	1
Low	58	341.2	25	7.3	1.4	(0.82–2.53)	0.0239^c

Notes: ^aMortaility density was displayed as per 100 people-years. ^baHR was adjusted for gender and age. ^caHR was adjusted for gender, age and histological grade.

Abbreviations: CIP2A, cancerous inhibitor of protein phosphatase 2A; OSCC, oral squamous cell carcinoma; AJCC, American Joint Committee on Cancer